Novo Nordisk set to finalize $11bn acquisition of Catalent manufacturing sites
Novo Nordisk is set to finalise its acquisition of three Catalent manufacturing sites, marking a pivotal step in its strategy to bolster global manufacturing capabilities ... Read More
Hims & Hers’ earnings soar while GLP-1 drug crisis deepens—what this means for investors
Hims & Hers Health Inc. saw its stock surge following a robust quarterly earnings report, which showcased significant growth in revenue and subscriber numbers. Despite ... Read More
Novo Nordisk stock climbs 1.52% as obesity drug Liraglutide shows promise in young kids
Novo Nordisk A/S shares climbed by 1.52% today to 888.60 DKK, following the release of promising new data on its obesity drug Liraglutide, which has ... Read More
Setback for diabetes innovation: FDA puts brakes on Novo Nordisk’s once-weekly insulin icodec
Novo Nordisk announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application for its ... Read More
Novo Nordisk faces setback as CLARION-CKD trial fails, leading to significant financial impairment
Novo Nordisk, a global leader in pharmaceuticals, has announced a major setback as its CLARION-CKD phase 3 trial failed to meet its primary endpoint, prompting ... Read More
Novo Nordisk announces $4.1bn investment in new North Carolina manufacturing facility
Novo Nordisk, a global leader in pharmaceutical manufacturing, has unveiled plans to invest $4.1 billion (approximately 27 billion Danish kroner) to establish a second fill ... Read More
Novo Nordisk announces significant outcomes for Mim8 in FRONTIER 2 trial
Novo Nordisk, a global healthcare leader, has announced significant outcomes from the FRONTIER 2 trial, a pivotal phase 3a study, underscoring the effectiveness of its ... Read More
Novo Nordisk to acquire Cardior Pharmaceuticals to expand cardiovascular portfolio
In a significant move within the pharmaceutical industry, Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to 1.025 billion Euros. This strategic acquisition ... Read More
FDA approves Novo Nordisk’s Wegovy for cardiovascular risk reduction in adults with obesity
The U.S. Food and Drug Administration (FDA) has recently granted an additional indication for Novo Nordisk's Wegovy, a milestone in medical advancements aimed at combating ... Read More
Novo Nordisk announces $11bn acquisition of fill-finish sites to boost global manufacturing
In a strategic move to enhance its global manufacturing capabilities, Novo Nordisk has announced a significant acquisition from Novo Holdings A/S, involving three fill-finish sites, ... Read More